Related references
Note: Only part of the references are listed.Four-Factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants
Ilanit Zada et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2021)
Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor-Associated Bleeding: A Retrospective Study
H. Andrew Wilsey et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2021)
Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage
Abdalla A. Ammar et al.
NEUROCRITICAL CARE (2021)
Real world utilization of Andexanet Alfa at a community hospital
Anthony Santarelli et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2021)
Utilization of 4-Factor Prothrombin Complex Concentrate for Reversal of Oral Factor Xa Inhibitor-Associated Acute Major Bleeding: A Case Series
Tessa R. Reynolds et al.
JOURNAL OF PHARMACY PRACTICE (2021)
A Low-Dose 4F-PCC Protocol for DOAC-Associated Intracranial Hemorrhage
Karen Berger et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2020)
Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients
Teresa A. Allison et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2020)
Real-world utilization of andexanet alfa
Caitlin S. Brown et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2020)
Factor Xa Inhibitor-Related Intracranial Hemorrhage Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates
Nicholas G. Panos et al.
CIRCULATION (2020)
30 DAY MORTALITY FOLLOWING ANDEXANET ALFA IN ANNEXA-4 COMPARED WITH PROTHROMBIN COMPLEX CONCENTRATE (PCC) THERAPY IN THE ORANGE STUDY FOR LIFE THREATENING NON-VITAMIN K ORAL ANTICOAGULANT (NOAC) RELATED BLEEDING
Alexander Thomas Cohen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages
Megan E. Barra et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Multi-centered evaluation of a novel fixed-dose four-factor prothrombin complex concentrate protocol for warfarin reversal
Scott K. Dietrich et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2020)
An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage
Amarilis Giovino et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2020)
2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants A Report of the American College of Cardiology Solution Set Oversight Committee
Gordon F. Tomaselli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa
Charlie J. Nederpelt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation
Genmin Lu et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers
Genmin Lu et al.
BLOOD ADVANCES (2020)
WORLDWIDE ORAL ANTICOAGULANT PRESCRIPTION PREVALENCE AND TRENDS IN PATIENTS WITH ATRIAL FIBRILLATION FROM A MULTI-NATIONAL COHORT: INSIGHTS FROM THE INTERNATIONAL COLLABORATIVE PARTNERSHIP FOR THE STUDY OF ATRIAL FIBRILLATION (INTERAF) COLLABORATIVE
Jonathan Chong Hsu et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
S. J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study
Melanie N. Smith et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors
Oliver Grottke et al.
ANESTHESIOLOGY (2019)
Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage
Daniel Dybdahl et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2019)
Andexanet alfa-The first 150 days
Sarah E. Culbreth et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate
Marwan Sheikh-Taha
INTERNAL AND EMERGENCY MEDICINE (2019)
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
Adam Cuker et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis
Siavash Piran et al.
BLOOD ADVANCES (2019)
European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage
Hanne Christensen et al.
EUROPEAN STROKE JOURNAL (2019)
Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center
Victoria M. Stevens et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2019)
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers
J. H. Levy et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Association of Prothrombin Complex Concentrate Administration and Hematoma Enlargement in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage
Stefan T. Gerner et al.
ANNALS OF NEUROLOGY (2018)
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
Sam Schulman et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Predicting Prognosis of Intracerebral Hemorrhage (ICH): Performance of ICH Score Is Not Improved by Adding Oral Anticoagulant Use
Rik Houben et al.
FRONTIERS IN NEUROLOGY (2018)
Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report
Gregory Y. H. Lip et al.
CHEST (2018)
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy
Daniel M. Witt et al.
BLOOD ADVANCES (2018)
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
Ammar Majeed et al.
BLOOD (2017)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage
E. Herzog et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors
Ramesh Grandhi et al.
WORLD NEUROSURGERY (2015)
Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate
Hamim Zahir et al.
CIRCULATION (2015)
The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis
Chatree Chai-Adisaksopha et al.
BLOOD (2014)
Four-Factor Prothrombin Complex Concentrate for Urgent Reversal of Vitamin K Antagonists in Patients With Major Bleeding
Daniel J. Quinlan et al.
CIRCULATION (2013)
Accuracy and Clinical Usefulness of Intracerebral Hemorrhage Grading Scores A Direct Comparison in a UK Population
Adrian R. Parry-Jones et al.
STROKE (2013)
Comparison of ABC/2 estimation technique to computer-assisted planimetric analysis in warfarin-related intracerebral parenchymal hemorrhage
HB Huttner et al.
STROKE (2006)
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa
KA O'Connell et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Share Paper
